Get Social With Us

The Pros and Cons of Using Platform Approaches for Early Development of Monoclonal Antibodies: When Do We Deviate from the Platform?

Presented at: IBC’s Preclinical Scale Bioprocessing Boston, MA, November 3, 2009

Platform technologies are used by most organizations today in conjunction with product development. Deviating from the use of an organization’s standard platform requires consideration of the alternative’s rewards versus risks, the pros and cons of the alternative versus the standard approach, and the company’s strategic goals. Risks sometimes carry ample rewards and newer technologies most likely to challenge prevailing platforms are reviewed.